Cello Therapeutics’ Platelet Membrane-Coated Nanoparticles Offer a Novel Platform for the Delivery of Immunotherapy in Cancer Treatment
Excerpt from the Press Release:
SAN DIEGO, March 31, 2021 (GLOBE NEWSWIRE) — Solid tumors comprise about 90% of all newly diagnosed cancer cases and cancer deaths according to an annual report from the National Cancer Institute. Despite the relative “ease” of surgical resection of such tumors, there lies significant risk in the recurrence of the tumor due to incomplete removal of tumor cells or from metastasis, making new treatment options such as immunotherapy urgently needed to control and eliminate these tumors.
In a new study published today in Nature Communications, Cello Therapeutics shows how semisynthetic nanoparticles coated in platelet membrane can effectively inhibit tumor growth and metastasis in multiple mouse models of solid tumors. Cello collects the membrane of human platelets and coats them onto synthetic nanoscale particle cores loaded with a toll-like receptor (TLR) agonist to create a formulation dubbed “PNP-R848.” See the article at: https://rdcu.be/chOMZ
Platelets have been implicated in many disease pathologies, including tumor progression. Previous studies have shown that platelets naturally bind to both cancer cells and components of the tumor microenvironment. In addition, platelets have even been shown to facilitate metastasis by binding to circulating tumor cells and “hiding” them from detection.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?